Cipla Signs an Exclusive License Agreement with Bio-Thera for its BAT1706 (bevacizumab- biosimilar)
Shots:
- Cipla to get exclusive commercialization rights for Bio-Thera’s BAT1706 in certain countries. Bio-Thera will be responsible for its development & product approval with FDA & EMA
- In 2020- Bio-Thera plans to file an NDA to NMPA (CMPA)- EMA and the US FDA for BAT1706 approval
- Avastin’s biosimilar BAT1706 is a mAb- evaluated in P-III for patients with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC) and is approved in six indications including metastatic colorectal cancer (m CRC)- recurrent glioblastoma and non-squamous non-small cell lung cancer (NSCLC)
Ref: Businesswire| Image: Cipla Blog
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
